Corcept Therapeutics INC Form 4 insider transactions

Gary Charles Robb, Chief Business Officer of Corcept Therapeutics, sold 2,609 shares and gifted 300 shares of company stock, according to a recent SEC Form 4 filing.

A Corcept Therapeutics officer, Joseph Douglas Lyon, sold 1,411 shares of common stock at $56.72 per share on November 22, 2024.

A Corcept Therapeutics director, Daniel N. Swisher Jr., exercised stock options and sold shares on November 11, 2024, according to a recent SEC filing.

William Guyer, Chief Development Officer of Corcept Therapeutics, executed stock options and sold shares under a pre-arranged 10b5-1 trading plan.

William Guyer, Chief Development Officer of Corcept Therapeutics, exercised stock options and sold 10,000 shares of common stock on October 1, 2024, under a pre-arranged 10b5-1 trading plan.

Gary Charles Robb, Chief Business Officer of Corcept Therapeutics, exercised stock options and sold shares on October 1, 2024, according to a Form 4 filing with the SEC.

Chief Business Officer Gary Charles Robb reported gifting shares and holding shares in custodial accounts for a child.

Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics, reports stock transactions including tax withholding and purchase plan acquisitions.

Atabak Mokari, CFO of Corcept Therapeutics, reports the acquisition and disposal of company stock, including shares withheld for tax obligations and shares purchased under a company purchase plan.

Sean Maduck, President of Corcept Endocrinology, reports acquisition and disposal of Corcept Therapeutics (CORT) stock, including shares withheld for tax obligations and shares purchased under an incentive plan.

William Guyer, Chief Development Officer of Corcept Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Gary Charles Robb, Chief Business Officer of Corcept Therapeutics, reports acquisition and disposal of company stock, including shares withheld for tax obligations and shares purchased under an incentive award plan.

Gary Charles Robb, Chief Business Officer of Corcept Therapeutics, sold 3,101 shares of common stock at $35.71 per share on August 26, 2024.

Director Daniel N. Swisher, Jr. of Corcept Therapeutics reports the exercise of stock options and subsequent sale of shares on August 1, 2024.

William Guyer, Chief Development Officer of Corcept Therapeutics, exercised stock options and sold 10,000 shares of common stock on August 1, 2024, according to a recent SEC filing.

Hazel Hunt, Chief Scientific Officer of Corcept Therapeutics, exercised stock options and sold shares to cover the exercise price and tax obligations on August 1, 2024.

CEO Joseph K. Belanoff exercised stock options and sold shares of Corcept Therapeutics on July 31, 2024, to cover the exercise price and associated tax liabilities.

Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics, exercised stock options and sold shares on July 1, 2024, according to a recent SEC filing.

William Guyer, Chief Development Officer of Corcept Therapeutics, exercised stock options and sold 10,000 shares of common stock on July 1, 2024, according to a recent SEC filing.

Gary Robb, Chief Business Officer of Corcept Therapeutics, exercised stock options and sold shares on July 1, 2024, according to a Form 4 filing with the SEC.

Director Daniel N. Swisher Jr. exercised stock options and sold shares of Corcept Therapeutics on July 1, 2024, according to a Form 4 filing with the SEC.

Gary Robb, Chief Business Officer of Corcept Therapeutics, reports changes in beneficial ownership of company stock, including stock grants, transfers, and holdings in custodial accounts.

Gary Charles Robb, Chief Business Officer of Corcept Therapeutics, exercised stock options and sold shares to cover the exercise price and tax obligations on June 4, 2024.

Gary Robb, Chief Business Officer of Corcept Therapeutics, reports acquiring and disposing of company stock, including shares withheld for tax obligations and purchases under an incentive plan.

Joseph Douglas Lyon, Chief Accounting & Technology Officer of Corcept Therapeutics, reports the acquisition and disposal of company stock, including transactions under a 10b5-1 plan and a purchase plan.

Director Daniel N. Swisher Jr. exercised stock options and sold shares of Corcept Therapeutics under a pre-arranged 10b5-1 trading plan.

Sean Maduck, President of Corcept Endocrinology, reports the withholding of shares to cover tax obligations related to vesting restricted stock units.

William Guyer, Chief Development Officer of Corcept Therapeutics, exercised stock options and sold 10,000 shares of common stock at $32 per share on June 3, 2024, according to a recent SEC filing.

Atabak Mokari, CFO of Corcept Therapeutics, reports the acquisition and disposal of company stock, including shares withheld for tax obligations and shares purchased under a company purchase plan.

Gary Robb, Chief Business Officer of Corcept Therapeutics, exercised stock options and sold 11,000 shares of common stock on May 28, 2024, according to a recent SEC filing.